Concepedia

Carl Griffin

CG

6

Publications

435

Citations

6

H-Index

2020

Active since

Affiliations

Moderna Therapeutics (United States)(Current)

Lynn University

Emory University

Lynn Health Science Institute

Vanderbilt University Medical Center

Carl Griffin is an author at Moderna Therapeutics (United States) specializing in vaccine safety, vaccination, and immunology.

Top concepts

Publications per year

2020–2024

6

Publications

6

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

Donald Hurley, Carl Griffin, Mariano Young et al. · Clinical Infectious Diseases · 2020 · 156 citations · Full text

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

Evan J. Anderson, C. Buddy Creech, Vladimir Berthaud et al. · New England Journal of Medicine · 2022 · 136 citations · Full text

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Timo Vesikari, Joanne M. Langley, Nathan Segall et al. · The Lancet Infectious Diseases · 2021 · 70 citations

, , +8

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx et al. · The Lancet Infectious Diseases · 2024 · 41 citations

, , +6

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial

Hana M. El Sahly, Lindsey R. Baden, Brandon Essink et al. · The Journal of Infectious Diseases · 2022 · 19 citations · Full text

Rows per page

1–5 of 6